Sterling Pharmaceutical Recalled Nine Eye Product Lines
Retailers and distributors must pull inventory for nine eye drop and ointment brands due to sterility concerns.
Updated on Sept. 29, 2026 in Consumer Goods
Live Poll
Do you generally trust the safety of over-the-counter eye products sold at major retail stores?
Sterling Pharmaceutical Services issued a nationwide recall on August 20, 2026, for nine over-the-counter eye drop and ointment products. The recall, classified as Class II by the FDA, stems from the manufacturer's inability to confirm that production processes guaranteed product sterility.
Why it matters
Operators holding these products face immediate inventory removal to ensure compliance with FDA safety standards and mitigate liability risks. The recall highlights ongoing supply chain risks regarding the sterilization of ophthalmic goods manufactured without confirmed sterile process assurance.
The recall involves nine distinct eye drop and ointment product lines across brands including Walgreens, AvKare, and Major. Recalled units are identified by lot numbers ranging from 3161 to 3336, with expiration dates spanning August 2026 through July 2027.
The players
Sterling Pharmaceutical Services
An Illinois-based manufacturer of over-the-counter ophthalmic products and medical supplies.
FDA
The federal agency responsible for protecting public health through the regulation of food, drugs, and medical devices.
The details
The recall was initiated after Sterling Pharmaceutical Services could not provide sufficient assurance that its manufacturing environment maintained sterility for the affected eye products. Retailers must cross-reference their current stock against the specified lot range of 3161 to 3336 to identify impacted units. The lack of documented sterility protocols necessitates an immediate cessation of sales for these items until the recall process is cleared.
Timeline
Recalls for Sterling Pharmaceutical Services products began on August 20, 2026.
The FDA formally classified the action as a Class II recall during the week of September 25, 2026.
Affected products have expiration dates ranging from August 2026 through July 2027.
Market Landscape
The FDA Class II recall classification system provides the standard regulatory threshold for products that may cause temporary or medically reversible adverse health consequences, a framework that consistently governs how retailers handle defective health inventory. This action follows the established regulatory precedent for pulling products from the market when a manufacturer cannot provide verifiable evidence of a sterile production environment.
Retailers and pharmacy operators should audit their inventory for the specified lot numbers 3161 through 3336 immediately to prevent further sales. Consult with legal counsel to ensure that return procedures for the recalled items meet FDA Class II compliance requirements.
The takeaway
The lack of verifiable sterility protocols in manufacturing presents an acute inventory risk that requires immediate auditing of stock. Operators should verify that all current ophthalmic product shipments include updated certificates of analysis regarding sterilization testing.
Further reading
For broader trends in product safety compliance, visit the Consumer Goods section.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you generally trust the safety of over-the-counter eye products sold at major retail stores?
